Navigation Links
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
Date:9/30/2009

ys. 55(3), 707-12 (2003)).

The presentation slides are available at www.celltherapeutics.com/investor_updates.

CTI has an existing license and co-development agreement with Novartis for OPAXIO, which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
3. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
6. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
7. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
10. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
(Date:2/27/2015)... 27, 2015  In recognition of Rare Disease Day ... global bleeding disorders community, CSL Behring announced ... (IUs) of protein therapies to the World Federation of ... which has worked to improve the lives of people ... supports the WFH,s Global Alliance for Progress (GAP) Program ...
(Date:2/27/2015)... 2015  Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology, announced today that ... will present live at VirtualInvestorConferences.com on March 5th. ... us for this Company update," said Mr. Murphy. ... launch of the exVive3D Liver, Bioprinted Human Tissue, ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... , PALO ALTO, Calif., Dec. 2 Varian, Inc. (Nasdaq: ... with the U.S. Securities and Exchange Commission its Annual Report on ... This Annual Report may be accessed through the Company,s web site ... on "10-K" in the table shown. Stockholders may receive a ...
... , NEW YORK, Dec. 2 ... is available in its catalogue: , Pharmaceutical ... http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html , Global pharma ... competition in generic markets, rising cost of new product ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5
(Date:3/1/2015)... 2015 Theme and plugin developers from ... pack for Final Cut Pro X entitled Transccordion. ... to any FCPX editors project.” Said Christiana Austin, CEO ... tools needed to easily drag and drop their accordion ... many different controls over the parameters of this transition ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... 28, 2015 The Heart Fit Clinic ... distributor of the machine. The Heart Fit Clinic is ... like a franchise model. The goal is to scale ... heart disease. To buy External Counterpulsation machines ... help individuals through this process and achieve the desired ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law ... by time limits. They stated that in many cases, missing ... even nullify it. Many a time, delays in making an ... under BC law. As a result, experts at Jiwa Law ... consult a personal injury lawyer in order to know more ...
(Date:2/28/2015)... 2015 The Mesothelioma Applied Research ... at the International Symposium on Malignant Mesothelioma on Monday, ... the Hyatt Regency Bethesda in Bethesda, Maryland. The following ... and commitment to the mission to cure mesothelioma. , ... be presented to Miriam Ratner. Miriam runs the Meso ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
... Cow Disease, also known as Bovine Spongiform Encephalopathy (BSE), affects ... control and the animal ultimately dies. Prion proteins are believed ... may contain these prion proteins and the disease might be ... drink its milk, according to a new study. ...
... has indicated the benefits of tomato and broccoli in the ... both the vegetables, are a great blessing in the reduction ... isolation. ,It is estimated that one out ... making it the most notorious of male cancers. Annually, 32,000 ...
... ‘present’ - the common cause of amnesia, also prevents victims ... in the present. ,Researchers, reporting their study ... Sciences at the Wellcome Trust Centre for Neuroimaging, University College ... the brain that is crucial in learning and memory. ...
... federal scanner, which has pointed out a 4% decline in ... Department of Health and Human Service has attributed this drop ... 1996 to 2003- to the spiraling growth in expenditures on ... ,The Agency for Healthcare Research and Quality in Health ...
... melanoma screening of adults age 50 or older appears ... screening programs, according to an article in the January ... only cancer for which incidence and death rates continue ... to be underused, according to background information in the ...
... may come true; for fat people and inventors. ,Scientists ... those of Britain are no exception. //Currently, two thirds of the ... has decided to put a morbidly obese figure of 2.2 million ... Imperial College London. ,Bloom’s quest is to create a chewing ...
Cached Medicine News:Health News:Tomato and Broccoli Combo may Help Fight Prostate Cancer 2Health News:Amnesia Halts Future Thinking: Study 2Health News:One-time Melanoma Screening Appears to Be Cost-effective for Elderly People 2Health News:Chew That Fat Away 2
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... peripheral nerve stimulator automatically ... nerve locator or a ... upon which patient lead ... NSL-5 electrode lead set, ...
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
... Tupper's Universal Hand Holder and Retractor ... the hand in any position needed. ... skin or tendon hooks, fixate the ... With the patient's hand held firmly, ...
Medicine Products: